Dual role of immunomodulation by anticancer chemotherapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 23296003.
- Also identified by DOI 10.1038/nm.3045 and PMC identifier 4045109.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The anticancer efficacy of conventional chemotherapies seems to be due, in part, to augmentation of the host immune reactivity. However, a new study reveals that two common chemotherapeutic agents, gemcitabine and 5-fluorouracil, can also activate immune regulatory cells, which stimulates the emergence of protumorigenic cytokines via inflammasome pathways, limiting the antitumor efficacy of the drugs (pages 57–64).
Medical subject headings
- Carrier Proteins
- Caspase 1
- Deoxycytidine
- Fluorouracil
- Inflammasomes
- Neoplasms